Our study suffered from several limitations; small number of patients included in our study could be attributed to financial issues, the relation of CD146 expression to Philadelphia chromosome was missing, the difference of expression of CD146 among different risk groups of B-ALL was not touched, and by the same token, the study was not bolstered by CD146 relations to adverse genetic features including TCF3-PBX1 fusion, MLL gene rearrangement, t(17:19), hypodiploidy, and intrachromosomal amplification of chromosome 21. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.